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isk Assessment for
efibrillator Therapy
l Trittico*
elley P. Anderson, MD, FACC
arshfield, Wisconsin
Defibrillator Surgery Often Unnecessary” and “Devices
an Interfere With Peaceful Death” were the titles of
ewspaper articles that Mr. Michael brought to our arrhyth-
ia service for a second opinion regarding implantable
ardioverter-defibrillator (ICD) therapy (1,2). Mr. Michael
names in this commentary are fictitious) is a 67-year-old
ith New York Heart Association (NYHA) functional class
I congestive heart failure (CHF) symptoms. He had a
yocardial infarction (MI) followed by 3-vessel coronary
ypass grafting (CABG) 6 years before. Left ventricular
jection fraction (LVEF) is 27%. An electrocardiogram
hows left bundle branch block. A Holter showed 334
remature ventricular complexes (PVCs) per hour and up to
beat runs of nonsustained ventricular tachycardia (NSVT).
test for T-wave alternans was indeterminate due to
requent PVCs (3).
See page 1150
The second patient, Sister Angela, is an 82-year-old
etired nun referred for treatment of NYHA functional class
II CHF symptoms. She has atrial fibrillation, intraventric-
lar conduction disturbance, severe renal impairment, and a
istory of anterior MI. An echocardiogram showed an-
eroapical aneurysm and LVEF 24%. The third patient, Mr.
ianni, is a 58-year-old diabetic with NYHA functional
lass II CHF referred for ICD implantation. He has a
istory of MI and CABG 3 years before. An echocardio-
ram showed global hypokinesis with ejection fraction 32%
nd QRS duration is 98 ms. None of the patients have a
istory of syncope or other symptoms suggestive of a
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Marshfield Clinic, Marshfield, Wisconsin. Dr. Anderson was a partici-
ating investigator for MUSTT (Multicenter Unsustained Ventricular Tachycardia
rial) as well as for other clinical trials related to implantable cardioverter-
efibrillators. Dr. Anderson has had no role in the design or analysis of MUSTT. Dr.a
nderson has no financial, commercial, or industrial relationships related to this
ommentary.ustained ventricular tachyarrhythmia or evidence of myo-
ardial ischemia.
The 2006 Guidelines for Management of Patients With
entricular Arrhythmias and the Prevention of Sudden
ardiac Death recommend ICDs for each of the 3 patients
t a class I level (4). However, it is up to the clinician to
etermine the benefits and risks of ICD therapy and to
nform the patient. The evidence suggests this is rarely
uccessful. Most ICD patients have major misconceptions,
ith over 50% believing that ICDs would save more than 50
ives per 100 over 5 years and more than 95% overestimating
he number of lives saved compared with the results of
CD-HeFT (Sudden Cardiac Death-Heart Failure Trial)
5,6). We told our 3 patients that 64% of patients similar to
hem enrolled in the SCD-HeFT study survived 5 years
ith standard therapy but that with an ICD 71% survived
6). Inappropriate decisions for ICD replacement in re-
ponse to safety advisories indicate that patients are also
oorly informed about the risks of ICD therapy to the level
f detail recommended (7). For each patient, we reviewed
ossible operative complications, device malfunctions and fail-
res, and the pain and psychiatric problems associated with
hocks. We also discussed follow-up requirements and medi-
al, occupational, and recreational restrictions.
Mr. Michael declined ICD therapy, citing a newspaper
tory that many ICD recipients “may not need them” (1).
e reviewed data that showed that patients like him with
requent PVCs and indeterminate T-wave alternans tests
re not at low risk for arrhythmic death (8,9). A second
ewspaper article reported repeated shocks near the end of
ife (2). We reassured Mr. Michael that his risk of cardio-
ascular deterioration and nonarrhythmic death was not
igh. This was based on the finding in the SCD-HeFT
tudy that NYHA functional class II patients had a 5-year
urvival that rose from 68% to 80% with an ICD (5).
urthermore, he had none of the predictors of early mor-
ality after ICD implantation reported by Parkash et al.
10): age 80 years, history of atrial fibrillation, creatinine
1.8 mg/dl, and NYHA functional class III or IV CHF.
atients like him had a 1-year mortality of only 4%.
ventually, Mr. Michael agreed to ICD therapy because of
is wife’s fear that he could drop dead at any time and that
he ICD could reduce this risk by about two-thirds (11).
In contrast, Sister Angela had all 4 risk factors for early
ortality in ICD recipients, indicating 1-year mortality over
0% (10). Moreover, the SCD-HeFT study showed that
atients with class III CHF did not benefit from ICD
mplantation, and the MADIT-II (Second Multicenter
utomatic Defibrillator Trial) Investigators showed that
everely impaired renal function predicted high mortality
nresponsive to ICD therapy (6,12). We assured Sister
ngela and her family that it was reasonable to decline ICD
herapy. Mr. Gianni demonstrated few of the risk factors
ssociated with worse mortality in MADIT-II (13,14),
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September 18, 2007:1158–60 Editorial CommentCD-HeFT (6), or in the study by Parkash et al. (10). He
id not wish to undergo further tests for risk assessment.
These 3 cases illustrate the importance of data to address
ndividual circumstances beyond the general findings of
andomized clinical trials and the need for an efficient risk
ssessment method. In this issue of the Journal, Buxton et al.
15) present a new algorithm to estimate the 2-year total
nd arrhythmic mortality in patients with LVEF40% due
o previous MI based on the MUSTT study. Applied to Mr.
ichael, the 2-year total mortality risk is 25% and the
rrhythmic death risk is 11%. These estimates are compa-
able to 2-year risks of total (22%) and arrhythmic death
12%) in the MADIT-II study conventional treatment
roup (13). If the ICD reduces arrhythmic death by 67% as
n MADIT-II, then Mr. Michael’s absolute and relative
ortality reduction would be 7% and 28%, respectively, by
years (11,13). For Sister Angela, the MUSTT algorithm
-year all-cause and arrhythmic mortality estimates are 78%
nd 6%, respectively. The high nonsudden mortality is
ompatible with the studies discussed earlier, and the low
rrhythmic risk reduces the potential impact of ICD therapy
nd provides a rationale for declining implantation. For Mr.
ianni, the algorithm yields a 2-year mortality risk of 10%
nd a malignant arrhythmia risk of 3.5%, compatible with
he absence of other indicators of poor prognosis.
Despite its apparent utility, the MUSTT algorithm
annot be assumed to provide accurate risk assessment for
everal reasons. One is that patients encountered in practice
ave different demographics, clinical characteristics, and
utcomes from those enrolled in clinical trials (16,17). In
ddition, changes in background and follow-up treatment
tandards since the MUSTT study was conducted should
mprove outcomes. Furthermore, the subgroup analysis on
hich the MUSTT algorithm is based may have low
eliability (18). Moreover, the mathematical functions used
o derive the algorithm may not adequately represent the
nderlying biological phenomena, and the modeled sample
ay have significant uncharacterized elements that affect
he model but are unrelated to risk.
Potential problems also exist with specific elements of the
lgorithm. Nonsustained ventricular tachycardia was an
ntry criterion, so all of the MUSTT patients have 17 points
dded to the arrhythmic risk score, except those few in
hom NSVT is detected 4 days to 10 days after CABG. In
ractice, however, the status of NSVT is often not known,
nd determining its presence or absence is not straightfor-
ard, because its detection depends on the frequency of
SVT episodes and the duration of monitoring. Detection
uring prolonged in-hospital monitoring is more likely but
ay be associated with a different prognosis. Inducible
entricular tachycardia, also assessed in all of the MUSTT
atients, adds 8 points to total mortality and 17 points to
he arrhythmic death/cardiac arrest score. In practice, how-
ver, many patients do not undergo electrophysiologic
tudies. Although Buxton et al. (15) stipulate that use of
heir model be restricted to patients with asymptomatic aSVT who have undergone programmed stimulation, this
ould severely reduce the utility of their algorithm. It is
oteworthy that age, atrial fibrillation, and NYHA func-
ional class contribute to total mortality, but not to arrhyth-
ic risk, consistent with some earlier studies (10). However,
t is surprising that no variable reflecting renal function was
dentified for the MUSTT risk estimator, because several
tudies have demonstrated a strong independent association
ith mortality. In particular, there is evidence of an associ-
tion between poor renal function and ICD-unresponsive
udden death (10–12).
Before it can be considered for wider clinical use, the
USTT algorithm must be modified to accommodate
atients with unknown status of NSVT and inducible
entricular tachycardia, and the role of renal function should
e addressed. The algorithm should be validated by apply-
ng it to clinically relevant test populations. It is important
o recognize that prediction of sudden death and cardiac
rrest does not necessarily predict ICD efficacy. Random-
zed clinical trials show a persistent risk of sudden death
espite ICD therapy that accounts for about one-third of
ardiac deaths in ICD recipients (11). Demonstration of
alue in predicting a survival advantage of ICD therapy
ould necessitate a relatively complex trial with randomiza-
ion of ICD therapy based on the algorithm. However, a
etrospective analysis of the algorithm in the MUSTT
atients who received ICDs might provide valuable data on
rediction of ICD-resistant death and appropriate ICD
herapy.
As our 3 patients illustrate, available risk stratification
ethods lack the precision and convenience that clinicians
eek and the certainty that patients crave to justify the
motional and physical consequences of ICD therapy. The
lgorithm developed by Buxton et al. (15) for patients with
revious MI has important advantages in that it provides
ne-stop shopping for the full spectrum of high-risk LVEF
40%) and NYHA CHF functional class (I to III), it is
asy to use, it can be repeatedly applied, and it is free.
owever, our enthusiasm is dampened by the failure of
undreds of risk assessment schemes developed during the
alf-century since Smirk (19) surmised that R-on-T PVCs
redict arrhythmic death and recommended administration
f quinidine to prevent it. As with any new technique, the
USTT risk estimator cannot be recommended for use in
atients until its accuracy is proved. Until then, we are
leased to try out (in monitor mode) this promising algo-
ithm to see how it compares with our other risk-
tratification tools.
cknowledgments
he author thanks the Marshfield Clinic Research Foun-
ation for its support through the assistance of Linda Weis
nd Alice Stargardt in the preparation of the manuscript.
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